MXPA02009895A - Proteinas de fusion de antigeno de nucleo de hepatitis b. - Google Patents

Proteinas de fusion de antigeno de nucleo de hepatitis b.

Info

Publication number
MXPA02009895A
MXPA02009895A MXPA02009895A MXPA02009895A MXPA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A
Authority
MX
Mexico
Prior art keywords
particles
loop
hbcag
sequences
core
Prior art date
Application number
MXPA02009895A
Other languages
English (en)
Inventor
David Rowlands
Original Assignee
Univ Leeds Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds Innovations Ltd filed Critical Univ Leeds Innovations Ltd
Publication of MXPA02009895A publication Critical patent/MXPA02009895A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La capsida del virus de hepatitis B (HBV) se elabora de una especie individual de proteina llamada el antigeno de nucleo (HBcAg) que se auto-ensambla en particulas. Las particulas son altamente inmunogenicas y son capaces de presentar epitopes heterologos al sistema inmunitario cuando los epitopes se insertan en una region expuesta en la superficie de las particulas llamada la "asa el". Los bloques de construccion estructural de las particulas son dimeros estrechamente asociados de HBcAg en los cuales las asas el adyacentes estan yuxtapuestas de forma cercana. Se propone que las secuencias insertadas en la asa el, se restrinjan conformacionalmente en las particulas ensambladas cuando se presentan en la proteina de nucleo monomerica. La invencion busca solucionar este problema al enlazar covalentemente proteinas de nucleo como copias en tandem, por ejemplo, como dimeros, de modo que se pueden hacer inserciones independientes en cada copia. Esto es particularmente util para la insercion de grandes secuencias en la asa el, debido a que permite que estas secuencias se inserten en solo una copia de la proteina de nucleo por repeticion en tandem, reduciendo de este modo las potenciales oposiciones conformacionales en el ensamble. De manera alternativa, se puede insertar una secuencia diferente en cada asa el de una repeticion en tandem, incrementando de esta manera la flexibilidad de las particulas de HBcAg como un sistema de distribucion de epitopes.
MXPA02009895A 2000-04-07 2001-04-09 Proteinas de fusion de antigeno de nucleo de hepatitis b. MXPA02009895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107118 2000-04-07
PCT/GB2001/001607 WO2001077158A1 (en) 2000-04-07 2001-04-09 Hepatitis b core antigen fusion proteins

Publications (1)

Publication Number Publication Date
MXPA02009895A true MXPA02009895A (es) 2004-09-06

Family

ID=8168351

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009895A MXPA02009895A (es) 2000-04-07 2001-04-09 Proteinas de fusion de antigeno de nucleo de hepatitis b.

Country Status (18)

Country Link
US (1) US7270821B2 (es)
EP (1) EP1268530B1 (es)
JP (1) JP4713809B2 (es)
KR (1) KR100808313B1 (es)
CN (1) CN100360556C (es)
AP (1) AP1836A (es)
AT (1) ATE336502T1 (es)
AU (1) AU784345B2 (es)
BR (1) BR0109919A (es)
CA (1) CA2405438C (es)
DE (1) DE60122300T2 (es)
DK (1) DK1268530T3 (es)
EA (1) EA200201077A1 (es)
ES (1) ES2269371T3 (es)
MX (1) MXPA02009895A (es)
PT (1) PT1268530E (es)
WO (1) WO2001077158A1 (es)
ZA (1) ZA200208967B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218514B1 (en) * 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
KR100465643B1 (ko) * 2001-09-28 2005-01-13 (주) 에이프로젠 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
EP1523334A2 (en) 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004085635A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Melan-a peptide analogue-virus-like-particle conjugates
CN100537762C (zh) * 2004-06-24 2009-09-09 中国人民解放军军事医学科学院野战输血研究所 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用
KR100687653B1 (ko) * 2005-05-13 2007-02-27 유기현 스타-델타 결선용 전자개폐기의 제어방법
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
RU2538162C2 (ru) 2009-09-03 2015-01-10 Пфайзер Вэксинс ЭлЭлСи Вакцина против pcsk9
GB0918679D0 (en) * 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
JP6199036B2 (ja) * 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CN102199217B (zh) * 2011-04-01 2013-03-27 中国人民解放军第三军医大学 乙型肝炎病毒多表位融合蛋白及其制备方法和应用
ES2668672T3 (es) 2011-04-15 2018-05-21 Osaka University Vacuna de ADN
EP2891497B1 (en) * 2012-08-31 2020-07-01 Osaka University Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
EP2931896B1 (en) * 2012-12-11 2019-01-16 Osivax SAS Modified coiled coil type proteins having improved properties
CA2914555A1 (en) * 2013-06-06 2014-12-11 David J Rowlands Single domain antibody display
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
GB201402890D0 (en) * 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
BR112019009221A2 (pt) 2016-11-11 2019-07-16 Fraunhofer Usa Inc proteína de fusão, método para produzir a proteína, composição, partícula semelhante a vírus, método para produzir partículas semelhantes a vírus, e método para induzir uma resposta imunológica em um sujeito
CN110343707B (zh) * 2019-05-30 2021-06-15 中国科学院生物物理研究所 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JP2514033B2 (ja) * 1987-05-20 1996-07-10 財団法人 癌研究会 Ｂ型肝炎ウィルスの複製を可能とする新規な培養細胞
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk ＨＢｃ融合蛋白粒子およびその製造方法
AU2540897A (en) 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
US20030021804A1 (en) * 1997-01-21 2003-01-30 Philip Needleman Immunological process for increasing the hdl cholestrol concentration
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
EP1218514B1 (en) * 1999-10-08 2006-04-26 Celltech Pharma Europe Limited Designing immunogens
US20040054139A1 (en) * 2000-06-22 2004-03-18 Mark Page Modification of hepatitis b core antigen
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis

Also Published As

Publication number Publication date
ES2269371T3 (es) 2007-04-01
AP2002002658A0 (en) 2002-12-31
AU4670601A (en) 2001-10-23
EP1268530A1 (en) 2003-01-02
US20040223965A1 (en) 2004-11-11
US7270821B2 (en) 2007-09-18
DE60122300D1 (de) 2006-09-28
CA2405438C (en) 2011-07-12
EP1268530B1 (en) 2006-08-16
KR20030009429A (ko) 2003-01-29
CA2405438A1 (en) 2001-10-18
JP2003530123A (ja) 2003-10-14
AU784345B2 (en) 2006-03-16
CN100360556C (zh) 2008-01-09
ZA200208967B (en) 2003-10-08
KR100808313B1 (ko) 2008-02-27
BR0109919A (pt) 2003-03-11
WO2001077158A1 (en) 2001-10-18
EA200201077A1 (ru) 2003-04-24
JP4713809B2 (ja) 2011-06-29
AP1836A (en) 2008-03-14
DE60122300T2 (de) 2007-08-30
DK1268530T3 (da) 2006-11-13
PT1268530E (pt) 2006-12-29
ATE336502T1 (de) 2006-09-15
CN1441807A (zh) 2003-09-10

Similar Documents

Publication Publication Date Title
MXPA02009895A (es) Proteinas de fusion de antigeno de nucleo de hepatitis b.
Neurath et al. Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus-neutralizing
AU6616301A (en) Modification of hepatitis b core antigen
CA2331846A1 (en) Expression vectors for stimulating an immune response and methods of using the same
NO20012760L (no) HBV kjerneantigenpartikler med multiple immunogene komponenter bundet via peptidligander
AU1000802A (en) Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid_A
MXPA05008677A (es) Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica.
CY1105600T1 (el) Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
Riedl et al. Binding immune‐stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
CN1874787B (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
Niedre‐Otomere et al. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre‐S1 antigens induce broadly reactive neutralizing antibodies
ATE290399T1 (de) Hbv/hcv virus-ohnliche particle
Prange et al. DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
ATE312846T1 (de) Monoklonale antikörper gegen hepatitis b virus
ATE367827T1 (de) Verfahren zur reduzierung der immunogenizität der variablen regionen von antikörpern
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection
Kniskern et al. The application of molecular biology to the development of novel vaccines
DE69814884D1 (de) Hepatitis b virale polypeptide
CN116694685A (zh) 自复制rna分子和手足口四价疫苗
Michel et al. DNA immunization to hepatitis B surface antigen [HBsAg] as an approach to prevention and therapy for hepatitis B

Legal Events

Date Code Title Description
FG Grant or registration